Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $15.3750.

IVA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning purchased a new stake in Inventiva in the second quarter worth approximately $32,000. Virtu Financial LLC purchased a new stake in Inventiva during the 4th quarter valued at $60,000. XTX Topco Ltd purchased a new stake in Inventiva during the 4th quarter valued at $84,000. Cerity Partners LLC bought a new position in shares of Inventiva during the 4th quarter valued at $93,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter worth $116,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

IVA stock opened at $4.78 on Friday. Inventiva has a 1-year low of $3.35 and a 1-year high of $7.98. The business has a fifty day moving average price of $4.51 and a 200-day moving average price of $5.03.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.